Voronoi opens Phase 1/2 trial testing oral EGFR drug against C797S resistance
VRN110755 enters the clinic in a field crowded with EGFR-mutant NSCLC programs, aiming at resistance mutations that current third-generation inhibitors don't cover.
Executive Summary
- Voronoi has moved an oral EGFR inhibitor into a Phase 1/2 trial aimed squarely at patients who have run out of options after standard EGFR-targeted therapy fails.
- The design targets resistance mutations that arise after third-generation inhibitors stop working, a segment current approved drugs do not fully cover.
- EGFR-mutant lung cancer is one of the most heavily worked targets in oncology, with dozens of industry programs and several approved drugs already anchoring the standard of care.
- The trial's early goal is establishing a tolerable dose and safety profile, the foundation any efficacy claim in this crowded space will need to stand on.
The trial
The study, known as REACH-EGFR, is recruiting patients with advanced or metastatic nonsquamous NSCLC carrying documented EGFR mutations. It started enrolling on March 26, 2024, and lists a primary completion date of January 1, 2029. The primary endpoints are dose-finding: estimating the maximum tolerated dose of VRN110755 and tracking dose-limiting toxicities over a 28-day evaluation window, alongside adverse events, ECG changes, and laboratory findings tracked through end of treatment. Secondary endpoints add objective response rate, duration of response, progression-free survival, overall survival, and intracranial response measures for patients with brain metastases. NCT07699328A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerNCT07699328
Who it targets
The trial's four cohort structure is built around resistance biology. Phase 1b Cohort A enrolls patients whose tumors carry an EGFR exon 19 deletion or L858R mutation plus a C797X resistance mutation, and who progressed after first-line treatment with a third-generation EGFR tyrosine kinase inhibitor, including osimertinib, lazertinib, or aumolertinib. Other cohorts cover treatment-naive patients with common EGFR mutations and patients with atypical mutations such as G719X, L861Q, and S768I who have exhausted standard options. That structure signals the trial is testing whether VRN110755 can work where the current standard of care runs out, not simply seeking to match it head-on. NCT07699328A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerNCT07699328
A crowded target
EGFR is one of the most worked targets in oncology. Industry search of trials sharing the EGFR target and non-small cell lung cancer indication turns up more than 80 peers, spanning small molecules, antibody-drug conjugates, and bispecific antibodies. Direct comparators competing on the same target and modality axis include osimertinib (AstraZeneca, Phase 4) and earlier-stage programs such as SHR-A2009 (Suzhou Suncadia, Phase 3) and BL-B01D1 (Sichuan Baili, Phase 2/3). Field-wide activity in EGFR has declined, with the number of recent trials running well below prior periods, a signal that the pace of new EGFR programs entering the clinic has slowed even as the target remains heavily populated.
Sponsor context
Voronoi carries a small industry pipeline: one other trial in its portfolio is completed, one is recruiting beyond this study, and one has not yet started recruiting. The trial's protocol has not been amended since registration and no prior status changes have been logged beyond the initial filing.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.